Senior Director, PM Portfolio Lead for Hematology at Bristol-Myers Squibb

Boudry, Neuchatel, Switzerland

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, Biotechnology, HematologyIndustries

Requirements

Provide line management leadership, coaching, and development for up to 10 Program Management (PM) team members
Oversee program and project execution for a specific therapeutic area portfolio (or subset) in Hematology
Serve as a business partner to Global Franchise Leads and Therapeutic Area Head
Act as interim Program Management Lead for an asset, operating as a strategic partner to the Global Program Lead (GPL)
Prioritize time between portfolio execution oversight and personnel line management
Partner with Global Franchise Lead(s) and Therapeutic Area Heads on PM/GPL assignments, performance, inflections points, decisions, acceleration opportunities, risk management, disease area strategies, and GPT Operating Model evolution
Hold team members accountable for Program and Project Management responsibilities, including ADP and indication development plans, integrated project schedules, critical path assessment, scenario planning, timeline visualizations, risk management, governance readiness, PM systems/processes, GPT budget/resource health, and PPM data quality
Maintain close oversight of key development inflection points within the portfolio
Serve as a thought partner to challenge ADPs and identify acceleration opportunities

Responsibilities

Direct oversight for PMs assigned to asset programs (GPT) and early/late development projects of varying scope and complexity
Deliver and grow PM team members as subject matter experts (SMEs)
Consistent oversight for upcoming asset and portfolio inflection points, decisions, and acceleration opportunities
Escalation and oversight for critical risk management at asset and indication levels, ensuring delivery by sub-teams and execution teams
Directly lead asset and indication level risk management activities
Leadership to ensure team readiness for governance
Delivery and adherence to established PM systems, processes, and ways of working
Oversight for GPT budget and resource health
Ensure team members' data and outputs meet PPM data quality expectations
Shape and deliver Target Product Profile (TPP) and Asset Development Plan (ADP) for assigned assets and indications as interim Program Management Lead

Skills

Program Management

Line Management

Leadership

Coaching

Portfolio Management

Project Execution

Therapeutic Area Oversight

Strategic Partnership

Target Product Profile

Asset Development Plan

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free